Momentum factor investing in healthcare biotech stocks is

Momentum factor investing in healthcare biotech stocks is triggering multi-month breakouts. With FDA fast-tracks boosting clinical pipeline valuations, 50-day momentum scores have reached levels last seen during the 2020 biotech surge. CFG is a Zacks Rank #2 (Buy) stock, with a Momentum Style Score of B and VGM Score of B. Shares are down 0.3% over the past one week and up 2.1% over the past four weeks. CFG has gained 30.8% in the last one-year period as well. Looking at trading volume, an average of 4,146,511 shares exchanged hands over the last 20 trading days. The strong performance of international equities compared to U.S. equities has been a notable discussion point so far this year, as it marks a reversal of a longstanding trend. While the overall performance of international equities, as shown by the MSCI EAFE Total Return Index, has been impressive, examining the drivers behind the asset class’s return can offer valuable insights for investors. Momentum factor investing in Latin American equities is supported by currency stability and rising commodity exports. Brazil’s Ibovespa momentum ranking has risen to the top quartile among emerging market indices, signaling sustained buying pressure.